Results 41 to 50 of about 2,050 (152)
, 2023 BACKGROUND: Bacterial infections are common in patients with cancer, and many bacteria have developed resistance to currently used antibiotics. OBJECTIVES: We evaluated the METHODS: Antimicrobial susceptibility testing was performed using CLSI-approved ...
Nesher, Lior +5 more
core +1 more source
, 2022 Eravacycline is a synthetic fluorocycline within the tetracycline class of antimicrobials. Eravacycline is active in vitro against several clinically important Gram-positive and Gram-negative bacteria.
Marx A. +9 more
core +1 more source
A Divergent Route to Eravacycline
, 2017 A convergent route to eravacycline (1) has been developed by employing Michael–Dieckmann cyclization between enone 3 and a fully built and protected left-hand piece (LHP, 2).
Magnus Ronn (3621005) +4 more
core +1 more source
, 2023 Jie Wu,1,2 Guangcun Zhang,3 Qiang Zhao,3 Lifeng Wang,3 Jiyong Yang,3 Junchang Cui1 1Department of Respiratory Diseases, The Eighth Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, People’s Republic of China; 2Medical School of ...
Zhang G +5 more
core
In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
, 2020 Background Eravacycline is a novel synthetic fluorocycline antibacterial approved for complicated intra-abdominal infections. Objectives The purpose of this study was to assess the in vitro activities of eravacycline and comparator antibiotics against ...
Miranda, Julie +10 more
core +1 more source
Inactivation of efflux pumps sensitized normal cells to eravacycline.
, 2021 The graph shows the CFUs after eravacycline treatment of E. coli BW25113, E. coli BW25113 ΔacrA, E. coli BW25113 ΔtolC, and E. coli BW25113 ΔacrB. Means ± SE are shown (n = 3). (TIF)
Karin Sauer (1993) +5 more
core +1 more source
, 2023 The main aim and objective of the research work is to develop an effective, sensitive, economical and simple reverse phase HPLC method for quantification of Eravacycline and its impurities in Eravacycline parenteral dosage form.
P.Venkata Prabhakara Rao, Syed Mastan Ali, P. Bharath, D.Ramachandran
core
Eravacycline for the treatment of intra-abdominal infections
, 2014 Introduction: There has been a dramatic increase in the incidence of multidrug-resistant pathogens over the past few years, which highlights the need for new anti-infective therapeutics.
Righi, Elda +5 more
core +1 more source
, 2021 [[abstract]]Several antimicrobial combination therapies are used to treat multiple drug resistant (MDR) and extensively drug resistant (XDR) Acinetobacter baumannii infections.
Yin, T;Lai, JJ;Huang, WC;Kuo, SC;Chiang, TT;Yang, YS;the ACTION study group
core +1 more source
Novel Tet(L) Efflux Pump Variants Conferring Resistance to Tigecycline and Eravacycline in Staphylococcus Spp. [PDF]
, 2021 Tigecycline is regarded as one of the few important last-resort antibiotics to treat complicated skin and intra-abdominal infections. Members of the genus Staphylococcus are zoonotic pathogens and pose a serious threat to public health.
Yao, Hong +5 more
core +1 more source